| 5/13/2024 | CV | Market Commentary: MKS convertibles offering eyed; Novavax up outright, down on hedge; Perficient active
|
| 5/13/2024 | CV | Market Commentary: Morning Commentary: MKS convertible notes offering eyed; Novavax adds in early trading
|
| 5/10/2024 | CV | Market Commentary: Pacira BioSciences expands on debut; Snap active; Novavax surges on vaccine deal
|
| 3/1/2023 | CV | Market Commentary: TPI Composites, Encore convertibles expand on debut; IG paper struggles; Novavax plunges
|
| 3/1/2023 | CV | Market Commentary: Morning Commentary: TPI Composites, Encore convertibles expand on debut; Novavax plunges
|
| 1/4/2023 | CV | Market Commentary: Convertibles well bid; Uber, Airbnb, Bill.com notes active; Novavax underperforms
|
| 12/28/2022 | CV | Novavax greenshoe exercised, ups 5% convertibles to $175.25 million
|
| 12/16/2022 | CV | Market Commentary: Novavax volatile outright, mixed on hedge; Guardant Health down; Exact Sciences up
|
| 12/16/2022 | CV | Market Commentary: Morning Commentary: Novavax convertible notes crumble on debut as broader equities sink
|
| 12/16/2022 | CV | New Issue: Novavax prices upsized $150 million five-year convertibles to yield 5%, up 25%
|
| 12/15/2022 | CV | Market Commentary: Novavax convertibles offering eyed, credit questioned; Airbnb active; Carnival lower
|
| 12/15/2022 | CV | Market Commentary: Morning Commentary: Novavax convertible notes offering eyed in otherwise quiet primary
|
| 12/14/2022 | CV | Market Commentary: Novavax on deck; iQIYI convertible notes drop ‘like a stone’; Uniti, Wolfspeed lower
|
| 12/14/2022 | CV | Novavax talks $125 million five-year convertible notes to yield 4.75%-5.25%, up 22.5%-27.5%
|
| 6/3/2022 | CV | Market Commentary: ConMed convertibles give back outright gains; Okta up post-earnings; Novavax below par
|
| 10/7/2021 | CV | Market Commentary: Sea surges in active trade; Square, LendingTree add with shares; Golar maturity eyed
|
| 10/7/2021 | CV | Market Commentary: Morning Commentary: Novavax convertibles trade with higher shares; Insmed notes eyed
|
| 10/6/2021 | CV | Market Commentary: Convertibles activity muted; Western Digital notes trade down; Novavax convertibles flat
|
| 10/6/2021 | CV | Market Commentary: Morning Commentary: Convertibles trade mildly; Western Digital down; Novavax flat
|
| 10/4/2021 | CV | Market Commentary: Morning Commentary: Southwest Airlines moves in convertibles secondary; primary inactive
|
| 7/20/2020 | CV | Market Commentary: LendingTree on tap; Colony Capital gains; American Airlines active; Novavax improves
|
| 6/25/2020 | CV | Market Commentary: PG&E mandatories in demand; Xeris Pharmaceuticals stock tanks on convertibles offering
|
| 6/15/2020 | CV | Market Commentary: Convertibles primary market quiet; Pioneer Natural, Southwest Airlines, Jazz volatile
|
| 1/22/2020 | CV | Market Commentary: Barclays synthetic on tap; BofA synthetic tied to Charter, Elanco equity units eyed
|
| 5/10/2019 | CV | Novavax adjusts conversion rate on 3.75% convertible notes due 2023
|
| 2/28/2019 | CV | Market Commentary: LivePerson oversubscribed, expands on debut; Applied Optoelectronics eyed; Novavax tanks
|
| 9/25/2018 | CV | Market Commentary: Convertibles market eyes CenterPoint Energy offering; Chesapeake Energy, Novavax active
|
| 1/11/2018 | CV | Market Commentary: Exact Sciences to price $500 million; market awaits Coupa; Wheeler adds on; AmTrust active
|
| 1/10/2018 | CV | Market Commentary: Coupa to price; Wheeler to add on; Sempra preferreds unmoved; AmTrust, Novavax soar
|
| 9/25/2017 | CV | Market Commentary: Air Transport, IAC/InterActive deals on tap; Marriott Vacations trades actively, better
|
| 7/25/2017 | CV | Market Commentary: Novavax loses ground; Pacira trial results disappoint; Medicines’ data positive, bonds flat
|
| 7/24/2017 | CV | Market Commentary: WebMD convertibles jump on KKR purchase news; Arconic results beat as bonds wane; Novavax up
|
| 7/18/2017 | CV | Market Commentary: Morning Commentary: Bellwether convertible issues in focus; DISH paper declines with stock
|
| 9/19/2016 | CV | Market Commentary: Convertibles quiet; Blackhawk drags outright, dollar neutral; PTC Therapeutics moves up
|
| 9/19/2016 | CV | Market Commentary: Morning Commentary: DepoMed’s convertibles trade just under 140; PTC Therapeutics poised to move up
|
| 9/16/2016 | CV | Market Commentary: Novavax plummets after failed trials: Intel up with stock on better guidance; Wheeler prices
|
| 9/16/2016 | CV | Market Commentary: Morning Commentary: Novavax plummets after failed trial for RSV vaccine candidate; Wheeler prices
|
| 2/25/2016 | CV | Market Commentary: Restoration Hardware drops on disappointing preliminary results; Chesapeake holds in
|
| 2/17/2016 | CV | Market Commentary: Planned Invacare deal looks cheap; Priceline 0.9% convertibles contract with higher shares
|
| 2/17/2016 | CV | Market Commentary: Morning Commentary: Planned Invacare looks cheap; Priceline 0.9% convertibles contract
|
| 2/5/2016 | CV | Novavax greenshoe exercised, lifts 3.75% convertibles to $325 million
|
| 2/3/2016 | CV | Market Commentary: Tesla Motors, LinkedIn holding in amid volatility; Illumina 0% convertibles slip below par
|
| 1/26/2016 | CV | Market Commentary: New, upsized Novavax gains on swap; energy unchanged despite higher oil, share prices
|
| 1/26/2016 | CV | Market Commentary: Morning Commentary: New Novavax notes trade up after upsizing, pricing beyond cheap end of talk
|
| 1/25/2016 | CV | New Issue: Novavax sells $300 million seven-year convertibles at 3.75%, up 22.5%
|
| 1/25/2016 | CV | Market Commentary: Novavax is year’s first new convertible, looks a few points cheap; Chesapeake down
|
| 1/25/2016 | CV | Market Commentary: Morning Commentary: Planned Novavax is year’s first new convertible, looks a few points cheap
|
| 1/25/2016 | CV | Novavax to price $200 million seven-year convertible notes to yield 2.75%-3.25%, up 27.5%-32.5%
|
| 3/16/2010 | CVHY | Novavax files $150 million shelf registration for stock, preferreds
|
| 4/29/2009 | CV | Novavax to retire $17 million of 4.75% convertibles, will pay 70% in cash, 30% in stock
|
| 11/22/2006 | CV | Novavax files $100 million shelf registration
|
| 12/21/2005 | BTCV | Novavax files $100 million shelf
|
| 7/19/2004 | CV | New Issue: Novavax sells $35 million 4.75%, up 17% convertible notes in private placement
|
